About Our Team
Helping to improve patient care and outcomes
with products that provide early and specific
insights into clinical conditions.
BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is a significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.
The Company’s flagship product is The NGAL Test, which has been designed to aid in the risk assessment of Acute Kidney Injury (AKI), a common clinical syndrome that can have severe consequences, including significant morbidity and mortality if not identified and treated early. With the aid of The NGAL Test, physicians can identify patients potentially at risk of AKI more rapidly than is possible with the current standard of care measurements, enabling earlier intervention and more tailored patient management strategies.
BioPorto is headquartered in Hellerup, Denmark, and is listed on the NASDAQ Copenhagen stock exchange. [CPH: BIOPOR]
The NGAL Test is CE Marked and available for IVD use in the European Union; registered in Canada, Korea, and several other countries; for Research Use Only in the United States.
Tony Pare was appointed Chief Executive Officer of BioPorto in November 2021. Tony has led product development, commercialization, marketing, operations, and business development in leading medical device and diagnostic companies for 25 years.
Previously, he was the Chief Commercial Officer at T2 Biosystems, a US Nasdaq-listed in vitro diagnostics company. He held the same role at Hemanext, a pre-commercial company marketing blood transfusion technology. Tony also held various leadership roles at Haemonetics, specializing in blood processing and diagnostic technologies. In addition to being CEO of BioPorto, Tony is actively participating on advisory boards, and mentoring startup medical technology companies in the Boston area.
He holds a Bachelor of Science in Marine Engineering and a Master’s of Engineering Administration from George Washington University.
Neil Goldman, CPA
EVP & CFO
Neil Goldman was appointed Executive Vice President and Chief Financial Officer in November 2021. Neil has spent most his career leading global manufacturing and distribution companies through meaningful revenue growth while managing their capital and scaling their operations.
Most recently, he served as the EVP and CFO of Chembio Diagnostics, a US Nasdaq-listed point-of-care diagnostics company. Previously, he served as EVP-Corporate Development and CFO of J.S. Held, a private equity-sponsored national consulting firm. Neil also held EVP, Chief Operating Officer, and CFO positions at Unwired Technology and then joined Delphi Corp., now Aptiv plc (NYSE: APTV), as a Global Finance Director following Delphi’s acquisition of Unwired. Unwired was a tier-1 automotive electronics manufacturer and portfolio company of American Capital. Neil began his career as an auditor and advanced into regional and national management consulting roles at Ernst & Young and Cap Gemini Ernst & Young.
Neil is a Certified Public Accountant and received a Bachelor of Science in Business-Accountancy from Miami University (Ohio).
Dr. Christopher Bird
Dr. Christopher Bird was appointed Chief Medical Officer of BioPorto in August 2019. Christopher has a robust scientific background and a track record of delivering strong results in business development, finance, sales, and marketing. He most recently served as Head of North American Medical and Scientific Affairs at Roche Diagnostics Corp., where he had responsibility for strategy and execution of all clinical education, study management and field support during his 10 year tenure. Chris has a BA in Physiology from Brigham Young University, a MA in Biochemistry and Molecular Biology from University of California Los Angeles, and a DPhil in Molecular Immunology from Oxford University, where he was an Abraham Scholar.
Vice President Global Marketing & US Commercialization
Jennifer excels at leading sales organizations through change such as growth, new markets, product launches and team integrations. Focusing on process and system improvements and developing methods and teams to consistently achieve revenue goals is the key to her success. Jennifer’s sales career has spanned both medical and high tech; she has a Masters Certificate from Wayne State and a Bachelor of Science from Alma College.
Chairman of the Board
Christopher Lindop joined BioPorto’s Board in August 2019. He has over 15 years of experience in senior finance leadership roles with public healthcare companies and currently serves as the CFO of Quotient Limited, a developer and manufacturer of transfusion diagnostic products. Previously Chris was CFO of Haemonetics Corporation and CFO of Inverness Medical Innovations. In addition to his executive experience, Mr Lindop was a non-executive director of Parexel International Corporation (NASDAQ: PRXL) from 2006, where he was chairman of the audit and finance committee and a member of the nominating and governance committee until its sale. Chris has also served as an audit partner with the Boston office of Ernst & Young LLP and with the Boston office of Arthur Andersen LLP. He holds a BA in Business from the University of Strathclyde (Scotland).
Vice Chairman of the Board
John McDonough currently serves as Chairman of the Board of Directors, and previously served as President and Chief Executive Officer, of T2 BioSystems, Inc., a diagnostics company focused on the rapid detection of sepsis-causing pathogens. From 2003 to 2007, John held several positions at Cytyc Corporation, a company focused on women’s health, and ultimately served as President of Cytyc Development Corporation. He designed and executed Cytyc Corporation’s growth strategy, expanding the company from a single product company with revenue of approximately $300 million to a diverse women’s health company with revenue of approximately $750 million. He also led the efforts that resulted in Cytyc’s acquisition by Hologic Inc. for over $6 billion in October 2007. John is currently a member of the Board of Directors at Solace Therapeutics and Cytrellis Biosystems. He earned his undergraduate degree in business from Stonehill College.
Michael S. Singer
Michael S. Singer has been a member of BioPorto’s Board of Directors since August 2019. He is currently Chief Scientific Officer (CSO) and co-founder of Cartesian Therapeutics, Inc., a US biotech company developing novel cellular immunotherapies to cure cancer. Prior to founding Cartesian, he was co-founder and CSO of Topokine Therapeutics, Inc., and of Health Honors Corporation. Michael’s experience also includes leading Translational Medicine at Novartis Institutes for Biomedical Research. He is a board-certified ophthalmologist and has been admitted to practice patent law. He has served as a Surgeon in the Veterans Health Administration and teaches at Harvard Medical School. Michael completed residency at Harvard and holds a BS, MD, and PhD from Yale University.
Jan Leth Christensen
Jan Leth Christensen, attorney-at-law, is currently a board member and partner at Lønberg & Leth Christensen Advokataktieselskab. He is Chairman of Havnens Bygningsudlejnings A/S, Best Ejendomme A/S, and Advokaternes Ejendomsadministration A/S, and serves as a member of the executive management and/or the board of directors of several other companies and foundations. Jan holds a Master’s degree in Law from the University of Copenhagen.
Don Hardison most recently served as President, Chief Executive Officer, and as a member of the Board of Directors of Biotheranostics, Inc., an oncology-focused molecular diagnostics company which was acquired by Hologic Inc. in February 2021. Prior to Biotheranostics, he was the President and Chief Executive Officer of Good Start Genetics, a molecular diagnostics company focused on reproductive health. Earlier in his career, he held many executive and senior management positions at a number of public companies including Laboratory Corporation of America and Quest Diagnostics, the two largest US clinical laboratories; Exact Sciences Corporation, a molecular diagnostics company; and SmithKline Beecham Corporation, a pharmaceutical company. He currently serves on the Board of Directors of several privately held companies including Stemina Biomarker Discovery Inc., Seventh Sense Biosystems, and IQuity, Inc. He also served on the Board of Directors of Exact Sciences Corporation from May 2000, through its initial public offering in February 2001, until August 2007. He received his Bachelor of Arts in Political Science from the University of North Carolina, Chapel Hill.
Peter Mørch Eriksen
Peter Mørch Eriksen was appointed board member of BioPorto in November 2021. Peter has more than 20 years of MedTech and life science experience in Denmark and abroad. Prior to joining BioPorto, he was CEO of Sense A/S and before this role, he held positions as a Vice President of Medtronic in both the USA and Denmark. From these positions, Peter brings extensive experience in creating growth, restructuring, and funding in technology-intensive and complex companies. He has an accounting background supplemented by courses in management. In addition to being CEO of BioPorto, Peter chairs the board of FluoGuide, and is a member of Lund University Advisory Board. He also serves on the Medical Device and Diagnostics Advisory Committee of Cincinnati Children’s Hospital Medical Center in Ohio, US.